• +1-646-491-9876
    • +91-20-67278686

    Search

    Acute Lymphocytic Leukemia-Pipeline Review H1 2017

    Acute Lymphocytic Leukemia-Pipeline Review H1 2017

    • Report Code ID: RW0001834326
    • Category Pharmaceuticals
    • No. of Pages 786
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.

    Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3, 46, 53, 69 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 12, 18 and 2 molecules, respectively.

    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 7
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview 8
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development 9
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 36
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 54
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles 106
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 742
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 746
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 747
    Appendix 763

    List of Tables

    Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed GmbH, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celgene Corp, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectar Biosciences Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis SA, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Company, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gilead Sciences Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Humorigin Biotechnology Corp, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corp, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corp, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma NV, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Medivir AB, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mesoblast Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NantKwest Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NBE-Therapeutics AG, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Nimbus Therapeutics LLC, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corp, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTartis Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oribase Pharma, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OSE Immunotherapeutics, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar SA, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Shire Plc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sorrento Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syros Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Takara Bio Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Targazyme Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Trillium Therapeutics Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xbrane Biopharma AB, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    4SC AG
    AbbVie Inc
    Actinium Pharmaceuticals Inc
    ADC Therapeutics Sarl
    Aeglea BioTherapeutics Inc
    Affimed GmbH
    Altor BioScience Corp
    Amgen Inc
    ARA Healthcare Pvt Ltd
    Ariad Pharmaceuticals Inc
    Array BioPharma Inc
    Atara Biotherapeutics Inc
    Bellicum Pharmaceuticals Inc
    Bexion Pharmaceuticals LLC
    Bio-Path Holdings Inc
    BioSight Ltd
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Calithera Biosciences Inc
    CanBas Co Ltd
    Cantargia AB
    Celgene Corp
    Cellectar Biosciences Inc
    Cellectis SA
    Cellular Biomedicine Group Inc
    Ceronco Biosciences
    Cielo Therapeutics Inc
    Constellation Pharmaceuticals Inc
    Cyclacel Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    Deciphera Pharmaceuticals LLC
    Eli Lilly and Company
    EpiZyme Inc
    Erytech Pharma SA
    Fate Therapeutics Inc
    Formula Pharmaceuticals Inc
    Gamida Cell Ltd
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Humorigin Biotechnology Corp
    iDD biotech SAS
    Immunomedics Inc
    Incyte Corp
    Interprotein Corp
    Jasco Pharmaceuticals LLC
    Jazz Pharmaceuticals Plc
    Johnson & Johnson
    Juno Therapeutics Inc
    Karyopharm Therapeutics Inc
    Kiadis Pharma NV
    Kite Pharma Inc
    Les Laboratoires Servier SAS
    medac GmbH
    Medivir AB
    Merck & Co Inc
    Mesoblast Ltd
    Millennium Pharmaceuticals Inc
    NantKwest Inc
    NBE-Therapeutics AG
    Nimbus Therapeutics LLC
    Novartis AG
    NovImmune SA
    NuCana BioMed Ltd
    Omeros Corp
    OncoTartis Inc
    OncoTherapy Science Inc
    Oncternal Therapeutics Inc
    Oribase Pharma
    OSE Immunotherapeutics
    Pfenex Inc
    Pfizer Inc
    Pharma Mar SA
    Polyphor Ltd
    Regeneron Pharmaceuticals Inc
    Sanofi
    Sareum Holdings Plc
    Seattle Genetics Inc
    Shire Plc
    Sorrento Therapeutics Inc
    Spectrum Pharmaceuticals Inc
    Sun Pharma Advanced Research Company Ltd
    SYNIMMUNE GmbH
    Syros Pharmaceuticals Inc
    Takara Bio Inc
    Targazyme Inc
    Threshold Pharmaceuticals Inc
    Tolero Pharmaceuticals Inc
    TRACON Pharmaceuticals Inc
    Tragara Pharmaceuticals Inc
    Trillium Therapeutics Inc
    Verastem Inc
    VioQuest Pharmaceuticals Inc
    Xbrane Biopharma AB
    ZIOPHARM Oncology Inc

    Request for Sample

    Report Url https://www.reportsweb.com//acute-lymphocytic-leukemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//acute-lymphocytic-leukemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//acute-lymphocytic-leukemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments